COMPANY

Intensity Therapeutics

HQ: Shelton, CT source · intensitytherapeutics.com ↗ · New England

We work with clinical manufacturing organizations to manufacture the clinical supplies of our current and any future product candidates. From public records Source · Mar 27, 2026

Keywords: oncology cancer Sarcoma,Soft Tissue Breast Cancer Head and Neck Cancer Squamous Cell Carcinoma Lymphoma Pancreatic Cancer Liver Cancer Colon Cancer Lung Cancer Bile Duct Cancer Chordoma of Sacrum Sarcoma INT230-6

Location: Shelton, CT · source · Aug 11, 2026

Profile checked Oct 10, 2026

$11.4MRaised (2 yrs)2Trials (company is sponsor)

Timeline

Oct 31, 2025 Raise Follow-on offering — Registered direct: $4M (total, as published), announced Oct 31, 2025. Source: SEC filing. source ↗
Jun 11, 2025 Raise Follow-on offering: $2M (total, as published), announced Jun 11, 2025. Source: SEC filing. source ↗
Apr 25, 2025 Raise Follow-on offering: $2.35M (total, as published), announced Apr 25, 2025. Source: SEC filing. source ↗
Nov 21, 2024 Raise Follow-on offering — Registered direct: $3M (total, as published), announced Nov 21, 2024. Source: SEC filing. source ↗
Jun 28, 2024 Trial start Phase 3: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) source ↗
Feb 9, 2017 Trial start 1: A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 source ↗

Upcoming milestones

2027-12 (ESTIMATED) · Phase 3 · A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) · NCT06263231

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $11.4M. Last 2 years.

Oct 31, 2025 Follow-on offering — Registered direct: $4M (total, as published), announced Oct 31, 2025. Source: SEC filing. source ↗
Jun 11, 2025 Follow-on offering: $2M (total, as published), announced Jun 11, 2025. Source: SEC filing. source ↗
Apr 25, 2025 Follow-on offering: $2.35M (total, as published), announced Apr 25, 2025. Source: SEC filing. source ↗
Nov 21, 2024 Follow-on offering — Registered direct: $3M (total, as published), announced Nov 21, 2024. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06263231	A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)	Phase 3	Recruiting	Jun 28, 2024	2027-12 (estimated)
NCT03058289	A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6	1	Completed	Feb 9, 2017	Feb 22, 2023 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2024-12-05 Raise Private raise (SEC Form D): $3.6M sold; issuer “INTENSITY THERAPEUTICS, INC.”. Verified from the SEC filing. SEC filing ↗